Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide
for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical
resection specimens will then be analyzed for biological alterations.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute